SNDX insider transactions
Syndax Pharmaceuticals Inc. (SNDX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for SNDX
- Chief Financial Officer Goldan Keith A. sold $22,351 worth of shares (1,177 units at $18.99), decreasing direct ownership by 0.84% to 139,252 units (SEC Form 4) (for withholding tax)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Executive Officer Metzger Michael A sold $130,025 worth of shares (6,847 units at $18.99), decreasing direct ownership by 1% to 484,843 units (SEC Form 4) (withholding tax)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Executive Officer Metzger Michael A sold $360,819 worth of shares (17,159 units at $21.03), decreasing direct ownership by 3% to 491,690 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Financial Officer Goldan Keith A. sold $71,705 worth of shares (3,410 units at $21.03), decreasing direct ownership by 2% to 140,429 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Executive Officer Metzger Michael A was granted 217,600 shares and sold $152,835 worth of shares (7,412 units at $20.62), increasing direct ownership by 70% to 508,849 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Financial Officer Goldan Keith A. acquired $10,337 worth of shares (1,219 units at $8.48), was granted 52,250 shares and sold $42,931 worth of shares (2,082 units at $20.62), increasing direct ownership by 56% to 143,839 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Jarrett Jennifer was granted 24,000 shares, increasing direct ownership by 27% to 114,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Huber Martin H. Jr. was granted 24,000 shares, increasing direct ownership by 30% to 103,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Head of R&D, CMO Botwood Nicholas A.J. was granted 60,000 shares, increasing direct ownership by 171% to 95,165 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Podlesak Dennis was granted 48,000 shares, increasing direct ownership by 25% to 239,763 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Rizo Aleksandra was granted 24,000 shares, increasing direct ownership by 96% to 49,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Katkin Keith was granted 24,000 shares, increasing direct ownership by 24% to 124,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Legault Pierre was granted 24,000 shares, increasing direct ownership by 27% to 114,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- SEC Form 4 filed by Syndax Pharmaceuticals Inc.4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Executive Officer Metzger Michael A exercised 157,307 shares at a strike of $10.90 and sold $2,582,021 worth of shares (157,307 units at $16.41) (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Podlesak Dennis sold $875,100 worth of shares (57,600 units at $15.19) and exercised 57,600 shares at a strike of $7.20 (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Financial Officer Goldan Keith A. acquired $10,335 worth of shares (1,226 units at $8.43), increasing direct ownership by 1% to 93,676 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Executive Officer Metzger Michael A sold $69,953 worth of shares (7,534 units at $9.29), decreasing direct ownership by 2% to 298,661 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Financial Officer Goldan Keith A. sold $12,033 worth of shares (1,296 units at $9.29), decreasing direct ownership by 1% to 92,450 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Financial Officer Goldan Keith A. bought 3,000 shares, increasing direct ownership by 3% to 93,746 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Head of R&D, CMO Botwood Nicholas A.J. bought $105,826 worth of shares (11,765 units at $8.99), increasing direct ownership by 50% to 35,165 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Huber Martin H. Jr. bought $44,950 worth of shares (5,000 units at $8.99), increasing direct ownership by 7% to 79,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Katkin Keith bought $91,120 worth of shares (10,000 units at $9.11), increasing direct ownership by 11% to 100,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- New insider Botwood Nicholas A.J. claimed ownership of 23,400 shares (SEC Form 3)3 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Executive Officer Metzger Michael A exercised 6,074 shares at a strike of $7.20, increasing direct ownership by 2% to 306,195 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Executive Officer Metzger Michael A exercised 7,814 shares at a strike of $7.20 and sold $117,564 worth of shares (7,814 units at $15.05) (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Financial Officer Goldan Keith A. sold $58,559 worth of shares (3,777 units at $15.50), decreasing direct ownership by 4% to 90,746 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Executive Officer Metzger Michael A sold $206,017 worth of shares (13,288 units at $15.50), decreasing direct ownership by 4% to 300,121 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- President, Head of R&D Gallagher Neil sold $71,597 worth of shares (4,618 units at $15.50), decreasing direct ownership by 5% to 85,095 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- President, Head of R&D Gallagher Neil was granted 41,900 shares, increasing direct ownership by 88% to 89,713 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Financial Officer Goldan Keith A. was granted 41,900 shares, increasing direct ownership by 80% to 94,523 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Executive Officer Metzger Michael A was granted 149,500 shares, increasing direct ownership by 91% to 313,409 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Podlesak Dennis was granted 50,000 shares, increasing direct ownership by 35% to 191,763 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Rizo Aleksandra was granted 25,000 shares (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Meury William was granted 25,000 shares, increasing direct ownership by 38% to 90,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Katkin Keith was granted 25,000 shares, increasing direct ownership by 38% to 90,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Jarrett Jennifer was granted 25,000 shares, increasing direct ownership by 38% to 90,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Huber Martin H. Jr. was granted 25,000 shares, increasing direct ownership by 51% to 74,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Director Legault Pierre was granted 25,000 shares, increasing direct ownership by 38% to 90,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Chief Financial Officer Goldan Keith A. bought $25,037 worth of shares (1,250 units at $20.03), increasing direct ownership by 2% to 52,623 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- SEC Form 4 filed by Rizo Aleksandra4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- SEC Form 3 filed by new insider Rizo Aleksandra3 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Goldan Keith A. acquired $36,227 worth of shares (2,045 units at $17.72) and was granted 46,700 shares, increasing direct ownership by 1,855% to 51,373 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Metzger Michael A was granted 146,250 shares, increasing direct ownership by 828% to 163,909 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Gallagher Neil was granted 47,813 shares (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Huber Martin H. Jr. was granted 17,000 shares, increasing direct ownership by 53% to 49,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Jarrett Jennifer was granted 17,000 shares, increasing direct ownership by 35% to 65,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Katkin Keith was granted 17,000 shares, increasing direct ownership by 35% to 65,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Podlesak Dennis was granted 34,000 shares, increasing direct ownership by 32% to 141,763 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Morrison Briggs was granted 17,000 shares, increasing direct ownership by 95% to 34,836 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Legault Pierre was granted 17,000 shares, increasing direct ownership by 35% to 65,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- Meury William was granted 17,000 shares, increasing direct ownership by 35% to 65,000 units (SEC Form 4)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- SEC Form 4: Morrison Briggs exercised 52,855 shares at a strike of $8.77 and sold $965,402 worth of shares (52,855 units at $18.27)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- SEC Form 4: Meury William exercised 83,000 shares at a strike of $8.02 and sold $1,697,810 worth of shares (83,000 units at $20.46)4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- SEC Form 4 filed by Morrison Briggs4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- SEC Form 4 filed by Goldan Keith A.4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- SEC Form 4 filed by Morrison Briggs4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- SEC Form 4 filed by Morrison Briggs4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- SEC Form 4 filed by Morrison Briggs4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)
- SEC Form 4 filed by Gallagher Neil4 - Syndax Pharmaceuticals Inc (0001395937) (Issuer)